Plain-English translation of NCT05093335 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging agent called , combined with a PET/CT scan, to see if it can better detect certain blood cancers (like lymphoma and myeloma) and solid tumors. The medication is injected into your bloodstream, and then a special scanner takes detailed pictures to show where cancer cells may be located. This type of imaging may help doctors find and understand your cancer better.
Current imaging scans don't always show all types of cancer clearly, especially certain blood cancers that don't light up well on standard scans. This trial is exploring whether this new medication can provide clearer pictures and help doctors diagnose and monitor these cancers more accurately.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive an injection of the imaging medication into your vein and then lie in a PET/CT scanner for approximately 1.5 hours while pictures are taken. Some participants may have two scans. The scan uses a very low radiation dose (similar to other medical imaging). You will need to be able to remain still during the scan, and the entire visit may take a few hours including preparation time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States